Pemetrexed Accord

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
25-01-2024
产品特点 产品特点 (SPC)
25-01-2024
公众评估报告 公众评估报告 (PAR)
29-01-2016

有效成分:

pemetrexed disodium hemipentahydrate

可用日期:

Accord Healthcare S.L.U.

ATC代码:

L01BA04

INN(国际名称):

pemetrexed

治疗组:

Antineoplastic agents

治疗领域:

Carcinoma, Non-Small-Cell Lung; Mesothelioma

疗效迹象:

Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

產品總結:

Revision: 10

授权状态:

Authorised

授权日期:

2016-01-18

资料单张

                                58
B. PACKAGE LEAFLET
59
PACKAGE LEAFLET: INFORMATION FOR THE USER
PEMETREXED ACCORD 25 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
pemetrexed
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist or
nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Pemetrexed Accord is and what it is used for
2.
What you need to know before you use Pemetrexed Accord
3.
How to use Pemetrexed Accord
4.
Possible side effects
5.
How to store Pemetrexed Accord
6.
Contents of the pack and other information
1.
WHAT PEMETREXED ACCORD IS AND WHAT IT IS USED FOR
Pemetrexed Accord is a medicine used in the treatment of cancer.
Pemetrexed Accord is given in combination with cisplatin, another
anti-cancer medicine, as treatment
for malignant pleural mesothelioma, a form of cancer that affects the
lining of the lung, to patients who
have not received prior chemotherapy.
Pemetrexed Accord is also given in combination with cisplatin for the
initial treatment of
patients with advanced stage of lung cancer.
Pemetrexed Accord can be prescribed to you if you have lung cancer at
an advanced stage if
your disease has responded to treatment or it remains largely
unchanged after initial
chemotherapy.
Pemetrexed Accord is also a treatment for patients with advanced stage
of lung cancer whose disease
has progressed after other initial chemotherapy has been used.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PEMETREXED ACCORD
DO NOT USE PEMETREXED ACCORD
-
if you are allergic to pemetrexed or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are breast-feed
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml of concentrate contains pemetrexed disodium hemipentahydrate
equivalent to 25 mg
pemetrexed.
One vial of 4 ml of concentrate contains pemetrexed disodium
hemipentahydrate equivalent to 100 mg
Pemetrexed.
One vial of 20 ml of concentrate contains pemetrexed disodium
hemipentahydrate equivalent to 500
mg pemetrexed.
One vial of 34 ml of concentrate contains pemetrexed disodium
hemipentahydrate equivalent to 850
mg pemetrexed.
One vial of 40 ml of concentrate contains pemetrexed disodium
hemipentahydrate equivalent to 1000
mg pemetrexed.
Excipient with known effect
Each ml of solution contains 8.4 mg (0.4mmol) of sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
A clear, colourless to pale yellow solution.
pH is between 7.0 - 8.5
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Malignant pleural mesothelioma
Pemetrexed Accord in combination with cisplatin is indicated for the
treatment of chemotherapy naïve
patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed Accord in combination with cisplatin is indicated for the
first line treatment of patients
with locally advanced or metastatic non-small cell lung cancer other
than predominantly squamous cell
histology (see section 5.1).
Pemetrexed Accord is indicated as monotherapy for the maintenance
treatment of locally advanced or
metastatic non-small cell lung cancer other than predominantly
squamous cell histology in patients
whose disease has not progressed immediately following platinum-based
chemotherapy (see section
5.1).
Pemetrexed Accord is indicated as monotherapy for the second line
treatment of patients with locally
advanced or metastatic non-small cell lung cancer other than
predominantly squamous cell histology
(see section 5.1).

                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 25-01-2024
产品特点 产品特点 保加利亚文 25-01-2024
公众评估报告 公众评估报告 保加利亚文 29-01-2016
资料单张 资料单张 西班牙文 25-01-2024
产品特点 产品特点 西班牙文 25-01-2024
公众评估报告 公众评估报告 西班牙文 29-01-2016
资料单张 资料单张 捷克文 25-01-2024
产品特点 产品特点 捷克文 25-01-2024
公众评估报告 公众评估报告 捷克文 29-01-2016
资料单张 资料单张 丹麦文 25-01-2024
产品特点 产品特点 丹麦文 25-01-2024
公众评估报告 公众评估报告 丹麦文 29-01-2016
资料单张 资料单张 德文 25-01-2024
产品特点 产品特点 德文 25-01-2024
公众评估报告 公众评估报告 德文 29-01-2016
资料单张 资料单张 爱沙尼亚文 25-01-2024
产品特点 产品特点 爱沙尼亚文 25-01-2024
公众评估报告 公众评估报告 爱沙尼亚文 29-01-2016
资料单张 资料单张 希腊文 25-01-2024
产品特点 产品特点 希腊文 25-01-2024
公众评估报告 公众评估报告 希腊文 29-01-2016
资料单张 资料单张 法文 25-01-2024
产品特点 产品特点 法文 25-01-2024
公众评估报告 公众评估报告 法文 29-01-2016
资料单张 资料单张 意大利文 25-01-2024
产品特点 产品特点 意大利文 25-01-2024
公众评估报告 公众评估报告 意大利文 29-01-2016
资料单张 资料单张 拉脱维亚文 25-01-2024
产品特点 产品特点 拉脱维亚文 25-01-2024
公众评估报告 公众评估报告 拉脱维亚文 29-01-2016
资料单张 资料单张 立陶宛文 25-01-2024
产品特点 产品特点 立陶宛文 25-01-2024
公众评估报告 公众评估报告 立陶宛文 29-01-2016
资料单张 资料单张 匈牙利文 25-01-2024
产品特点 产品特点 匈牙利文 25-01-2024
公众评估报告 公众评估报告 匈牙利文 29-01-2016
资料单张 资料单张 马耳他文 25-01-2024
产品特点 产品特点 马耳他文 25-01-2024
公众评估报告 公众评估报告 马耳他文 29-01-2016
资料单张 资料单张 荷兰文 25-01-2024
产品特点 产品特点 荷兰文 25-01-2024
公众评估报告 公众评估报告 荷兰文 29-01-2016
资料单张 资料单张 波兰文 25-01-2024
产品特点 产品特点 波兰文 25-01-2024
公众评估报告 公众评估报告 波兰文 29-01-2016
资料单张 资料单张 葡萄牙文 25-01-2024
产品特点 产品特点 葡萄牙文 25-01-2024
公众评估报告 公众评估报告 葡萄牙文 29-01-2016
资料单张 资料单张 罗马尼亚文 25-01-2024
产品特点 产品特点 罗马尼亚文 25-01-2024
公众评估报告 公众评估报告 罗马尼亚文 29-01-2016
资料单张 资料单张 斯洛伐克文 25-01-2024
产品特点 产品特点 斯洛伐克文 25-01-2024
公众评估报告 公众评估报告 斯洛伐克文 29-01-2016
资料单张 资料单张 斯洛文尼亚文 25-01-2024
产品特点 产品特点 斯洛文尼亚文 25-01-2024
公众评估报告 公众评估报告 斯洛文尼亚文 29-01-2016
资料单张 资料单张 芬兰文 25-01-2024
产品特点 产品特点 芬兰文 25-01-2024
公众评估报告 公众评估报告 芬兰文 29-01-2016
资料单张 资料单张 瑞典文 25-01-2024
产品特点 产品特点 瑞典文 25-01-2024
公众评估报告 公众评估报告 瑞典文 29-01-2016
资料单张 资料单张 挪威文 25-01-2024
产品特点 产品特点 挪威文 25-01-2024
资料单张 资料单张 冰岛文 25-01-2024
产品特点 产品特点 冰岛文 25-01-2024
资料单张 资料单张 克罗地亚文 25-01-2024
产品特点 产品特点 克罗地亚文 25-01-2024
公众评估报告 公众评估报告 克罗地亚文 29-01-2016